Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

U.S. demand outstripping supply of steroid treatment for COVID

Published 06/25/2020, 06:23 AM
Updated 06/25/2020, 06:25 AM
© Reuters. FILE PHOTO: An ampoule of Dexamethasone is seen in this picture illustration

© Reuters. FILE PHOTO: An ampoule of Dexamethasone is seen in this picture illustration

By Michael Erman

NEW YORK (Reuters) - Soaring hospital demand for the steroid dexamethasone, which British researchers say significantly reduces mortality among severely ill COVID-19 patients, is outstripping supply of the drug, but hospitals have so far been able to treat patients out of their inventories, according to Vizient Inc, a drug buyer for about half of U.S. hospitals.

Hospitals and other health-care customers advised by Vizient increased orders of the drug by more than 600% after the researchers announced their findings last week. Manufacturers were only able to fill around half of those orders, Vizient said.

"What we're hearing from our members is that they are able to treat the patients who do require dexamethasone - they are treating them and they have product," Steven Lucio, vice president of pharmacy solutions at Vizient, said in an interview. "The concern is, Can the market continue to sustain this?"

Vizient's data shows that hospitals are increasingly putting the drug into use to treat COVID-19 patients, confirming what several U.S. hospitals in hard-hit parts of the country told Reuters last week.

According to Oxford University researchers, dexamethasone reduced death rates by nearly a third among COVID-19 patients requiring mechanical breathing assistance.

The injectable version of dexamethasone has been in shortage in the U.S. since February of last year, according to the U.S. Food and Drug Administration.

Still, German drugmaker Fresenius SE (DE:FREG)'s Kabi unit - by far the largest supplier to the U.S. market - says it has good inventory on hand of the steroid and is ramping up production in three of its U.S. factories to meet the surging demand.

© Reuters. FILE PHOTO: An ampoule of Dexamethasone is seen in this picture illustration

"Fresenius Kabi is confident we can meet customers’ needs with COVID-related medicines such as dexamethasone," spokesman Matthew Kuhn said in an email.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.